Cargando…

Do P2Y12 receptor inhibitors prescribed poststroke modify the risk of cognitive disorder or dementia? Protocol for a target trial using multiple national Swedish registries

INTRODUCTION: The target of a class of antiplatelet medicines, P2Y12R inhibitors, exists both on platelets and on brain immune cells (microglia). This protocol aims to describe a causal (based on a counterfactual model) approach for analysing whether P2Y12R inhibitors prescribed for secondary preven...

Descripción completa

Detalles Bibliográficos
Autores principales: Hinwood, Madeleine, Nyberg, Jenny, Leigh, Lucy, Gustavsson, Sara, Attia, John, Oldmeadow, Christopher, Ilicic, Marina, Linden, Thomas, Åberg, N David, Levi, Chris, Spratt, Neil, Carey, Leeanne M, Pollack, Michael, Johnson, Sarah J, Kuhn, Georg Hans, Walker, Frederick R, Nilsson, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9086614/
https://www.ncbi.nlm.nih.gov/pubmed/35534077
http://dx.doi.org/10.1136/bmjopen-2021-058244
_version_ 1784704043667423232
author Hinwood, Madeleine
Nyberg, Jenny
Leigh, Lucy
Gustavsson, Sara
Attia, John
Oldmeadow, Christopher
Ilicic, Marina
Linden, Thomas
Åberg, N David
Levi, Chris
Spratt, Neil
Carey, Leeanne M
Pollack, Michael
Johnson, Sarah J
Kuhn, Georg Hans
Walker, Frederick R
Nilsson, Michael
author_facet Hinwood, Madeleine
Nyberg, Jenny
Leigh, Lucy
Gustavsson, Sara
Attia, John
Oldmeadow, Christopher
Ilicic, Marina
Linden, Thomas
Åberg, N David
Levi, Chris
Spratt, Neil
Carey, Leeanne M
Pollack, Michael
Johnson, Sarah J
Kuhn, Georg Hans
Walker, Frederick R
Nilsson, Michael
author_sort Hinwood, Madeleine
collection PubMed
description INTRODUCTION: The target of a class of antiplatelet medicines, P2Y12R inhibitors, exists both on platelets and on brain immune cells (microglia). This protocol aims to describe a causal (based on a counterfactual model) approach for analysing whether P2Y12R inhibitors prescribed for secondary prevention poststroke may increase the risk of cognitive disorder or dementia via their actions on microglia, using real-world evidence. METHODS AND ANALYSIS: This will be a cohort study nested within the Swedish National Health and Medical Registers, including all people with incident stroke from 2006 to 2016. We developed directed acyclic graphs to operationalise the causal research question considering potential time-independent and time-dependent confounding, using input from several experts. We developed a study protocol following the components of the target trial approach described by Hernan et al and describe the data structure that would be required in order to make a causal inference. We also describe the statistical approach required to derive the causal estimand associated with this important clinical question; that is, a time-to-event analysis for the development of cognitive disorder or dementia at 1, 2 and 5-year follow-up, based on approaches for competing events to account for the risk of all-cause mortality. Causal effect estimates and the precision in these estimates will be quantified. ETHICS AND DISSEMINATION: This study has been approved by the Ethics Committee of the University of Gothenburg and Confidentiality Clearance at Statistics Sweden with Dnr 937-18, and an approved addendum with Dnr 2019-0157. The analysis and interpretation of the results will be heavily reliant on the structure, quality and potential for bias of the databases used. When we implement the protocol, we will consider and document any biases specific to the dataset and conduct appropriate sensitivity analyses. Findings will be disseminated to local stakeholders via conferences, and published in appropriate scientific journals.
format Online
Article
Text
id pubmed-9086614
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-90866142022-05-20 Do P2Y12 receptor inhibitors prescribed poststroke modify the risk of cognitive disorder or dementia? Protocol for a target trial using multiple national Swedish registries Hinwood, Madeleine Nyberg, Jenny Leigh, Lucy Gustavsson, Sara Attia, John Oldmeadow, Christopher Ilicic, Marina Linden, Thomas Åberg, N David Levi, Chris Spratt, Neil Carey, Leeanne M Pollack, Michael Johnson, Sarah J Kuhn, Georg Hans Walker, Frederick R Nilsson, Michael BMJ Open Neurology INTRODUCTION: The target of a class of antiplatelet medicines, P2Y12R inhibitors, exists both on platelets and on brain immune cells (microglia). This protocol aims to describe a causal (based on a counterfactual model) approach for analysing whether P2Y12R inhibitors prescribed for secondary prevention poststroke may increase the risk of cognitive disorder or dementia via their actions on microglia, using real-world evidence. METHODS AND ANALYSIS: This will be a cohort study nested within the Swedish National Health and Medical Registers, including all people with incident stroke from 2006 to 2016. We developed directed acyclic graphs to operationalise the causal research question considering potential time-independent and time-dependent confounding, using input from several experts. We developed a study protocol following the components of the target trial approach described by Hernan et al and describe the data structure that would be required in order to make a causal inference. We also describe the statistical approach required to derive the causal estimand associated with this important clinical question; that is, a time-to-event analysis for the development of cognitive disorder or dementia at 1, 2 and 5-year follow-up, based on approaches for competing events to account for the risk of all-cause mortality. Causal effect estimates and the precision in these estimates will be quantified. ETHICS AND DISSEMINATION: This study has been approved by the Ethics Committee of the University of Gothenburg and Confidentiality Clearance at Statistics Sweden with Dnr 937-18, and an approved addendum with Dnr 2019-0157. The analysis and interpretation of the results will be heavily reliant on the structure, quality and potential for bias of the databases used. When we implement the protocol, we will consider and document any biases specific to the dataset and conduct appropriate sensitivity analyses. Findings will be disseminated to local stakeholders via conferences, and published in appropriate scientific journals. BMJ Publishing Group 2022-05-09 /pmc/articles/PMC9086614/ /pubmed/35534077 http://dx.doi.org/10.1136/bmjopen-2021-058244 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Neurology
Hinwood, Madeleine
Nyberg, Jenny
Leigh, Lucy
Gustavsson, Sara
Attia, John
Oldmeadow, Christopher
Ilicic, Marina
Linden, Thomas
Åberg, N David
Levi, Chris
Spratt, Neil
Carey, Leeanne M
Pollack, Michael
Johnson, Sarah J
Kuhn, Georg Hans
Walker, Frederick R
Nilsson, Michael
Do P2Y12 receptor inhibitors prescribed poststroke modify the risk of cognitive disorder or dementia? Protocol for a target trial using multiple national Swedish registries
title Do P2Y12 receptor inhibitors prescribed poststroke modify the risk of cognitive disorder or dementia? Protocol for a target trial using multiple national Swedish registries
title_full Do P2Y12 receptor inhibitors prescribed poststroke modify the risk of cognitive disorder or dementia? Protocol for a target trial using multiple national Swedish registries
title_fullStr Do P2Y12 receptor inhibitors prescribed poststroke modify the risk of cognitive disorder or dementia? Protocol for a target trial using multiple national Swedish registries
title_full_unstemmed Do P2Y12 receptor inhibitors prescribed poststroke modify the risk of cognitive disorder or dementia? Protocol for a target trial using multiple national Swedish registries
title_short Do P2Y12 receptor inhibitors prescribed poststroke modify the risk of cognitive disorder or dementia? Protocol for a target trial using multiple national Swedish registries
title_sort do p2y12 receptor inhibitors prescribed poststroke modify the risk of cognitive disorder or dementia? protocol for a target trial using multiple national swedish registries
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9086614/
https://www.ncbi.nlm.nih.gov/pubmed/35534077
http://dx.doi.org/10.1136/bmjopen-2021-058244
work_keys_str_mv AT hinwoodmadeleine dop2y12receptorinhibitorsprescribedpoststrokemodifytheriskofcognitivedisorderordementiaprotocolforatargettrialusingmultiplenationalswedishregistries
AT nybergjenny dop2y12receptorinhibitorsprescribedpoststrokemodifytheriskofcognitivedisorderordementiaprotocolforatargettrialusingmultiplenationalswedishregistries
AT leighlucy dop2y12receptorinhibitorsprescribedpoststrokemodifytheriskofcognitivedisorderordementiaprotocolforatargettrialusingmultiplenationalswedishregistries
AT gustavssonsara dop2y12receptorinhibitorsprescribedpoststrokemodifytheriskofcognitivedisorderordementiaprotocolforatargettrialusingmultiplenationalswedishregistries
AT attiajohn dop2y12receptorinhibitorsprescribedpoststrokemodifytheriskofcognitivedisorderordementiaprotocolforatargettrialusingmultiplenationalswedishregistries
AT oldmeadowchristopher dop2y12receptorinhibitorsprescribedpoststrokemodifytheriskofcognitivedisorderordementiaprotocolforatargettrialusingmultiplenationalswedishregistries
AT ilicicmarina dop2y12receptorinhibitorsprescribedpoststrokemodifytheriskofcognitivedisorderordementiaprotocolforatargettrialusingmultiplenationalswedishregistries
AT lindenthomas dop2y12receptorinhibitorsprescribedpoststrokemodifytheriskofcognitivedisorderordementiaprotocolforatargettrialusingmultiplenationalswedishregistries
AT abergndavid dop2y12receptorinhibitorsprescribedpoststrokemodifytheriskofcognitivedisorderordementiaprotocolforatargettrialusingmultiplenationalswedishregistries
AT levichris dop2y12receptorinhibitorsprescribedpoststrokemodifytheriskofcognitivedisorderordementiaprotocolforatargettrialusingmultiplenationalswedishregistries
AT sprattneil dop2y12receptorinhibitorsprescribedpoststrokemodifytheriskofcognitivedisorderordementiaprotocolforatargettrialusingmultiplenationalswedishregistries
AT careyleeannem dop2y12receptorinhibitorsprescribedpoststrokemodifytheriskofcognitivedisorderordementiaprotocolforatargettrialusingmultiplenationalswedishregistries
AT pollackmichael dop2y12receptorinhibitorsprescribedpoststrokemodifytheriskofcognitivedisorderordementiaprotocolforatargettrialusingmultiplenationalswedishregistries
AT johnsonsarahj dop2y12receptorinhibitorsprescribedpoststrokemodifytheriskofcognitivedisorderordementiaprotocolforatargettrialusingmultiplenationalswedishregistries
AT kuhngeorghans dop2y12receptorinhibitorsprescribedpoststrokemodifytheriskofcognitivedisorderordementiaprotocolforatargettrialusingmultiplenationalswedishregistries
AT walkerfrederickr dop2y12receptorinhibitorsprescribedpoststrokemodifytheriskofcognitivedisorderordementiaprotocolforatargettrialusingmultiplenationalswedishregistries
AT nilssonmichael dop2y12receptorinhibitorsprescribedpoststrokemodifytheriskofcognitivedisorderordementiaprotocolforatargettrialusingmultiplenationalswedishregistries